UPDATE | June 26, 2026

Data-centric organoid services for predictive drug response and next-generation oncology research

  • MAIL
Data centric organoid services for predictive drug response and next generation oncology research


Patient-derived organoids (PDOs) are becoming increasingly valuable translational models for oncology research, providing human-relevant insights into drug response, resistance, and tumor heterogeneity. As oncology drug development becomes more complex, integrating functional screening with molecular and clinical data is essential for more predictive decision-making.


This whitepaper explores how Samsung Organoids combines GxP-aligned patient-derived organoid screening with high-content screening (HCS), multi-omics analysis, and clinical data to generate clinically relevant, data-centric insights that support translational oncology research and drug development.


Key highlights include:
  • GxP-aligned organoid screening integrated with high-content screening (HCS), multi-omics analysis, and clinical data

  • Human-relevant translational models for evaluating drug response, resistance, and tumor heterogeneity

  • Functional drug-response data connected with genomic, transcriptomic, and clinical data

  • Clinically relevant data delivered through an integrated screening workflow in approximately five weeks

  • Process development and GMP manufacturing conducted within a single site to support early clinical development


Discover how data-centric organoid services can support more predictive oncology research and accelerate the transition from translational insights to clinical development.
Data centric organoid services for predictive drug response and next generation oncology research


Patient-derived organoids (PDOs) are becoming increasingly valuable translational models for oncology research, providing human-relevant insights into drug response, resistance, and tumor heterogeneity. As oncology drug development becomes more complex, integrating functional screening with molecular and clinical data is essential for more predictive decision-making.


This whitepaper explores how Samsung Organoids combines GxP-aligned patient-derived organoid screening with high-content screening (HCS), multi-omics analysis, and clinical data to generate clinically relevant, data-centric insights that support translational oncology research and drug development.


Key highlights include:
  • GxP-aligned organoid screening integrated with high-content screening (HCS), multi-omics analysis, and clinical data
  • Human-relevant translational models for evaluating drug response, resistance, and tumor heterogeneity
  • Functional drug-response data connected with genomic, transcriptomic, and clinical data
  • Clinically relevant data delivered through an integrated screening workflow in approximately five weeks
  • Process development and GMP manufacturing conducted within a single site to support early clinical development


Discover how data-centric organoid services can support more predictive oncology research and accelerate the transition from translational insights to clinical development.

Share article

Related Content

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required